Plasminogen activator inhibitor-1 (PAI-1) molecule: new physiological roles and clinical applications.
Takashi
T
Dan
Atsuhiko
A
Ichimura
Nicolas
N
Pelisch
Kazuhiko
K
Miyata
Koji
K
Akahori
Toshio
T
Miyata
D000375:Aging / Q000235:genetics; D000818:Animals; D001777:Blood Coagulation / Q000235:genetics; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D055808:Drug Discovery; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000235:genetics; D051379:Mice; D058990:Molecular Targeted Therapy; D018919:Neovascularization, Physiologic / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D017395:Plasminogen Activator Inhibitor 1 / Q000172:deficiency / Q000502:physiology*; D011658:Pulmonary Fibrosis / Q000188:drug therapy; D051381:Rats; D012038:Regeneration; D013927:Thrombosis / Q000188:drug therapy; D062366:para-Aminobenzoates / Q000627:therapeutic use*
C549556:5-chloro-2-(((2-(4-(diphenylmethyl)piperazin-1-yl)-2-oxoethoxy)acetyl)amino)benzoate; D005343:Fibrinolytic Agents; D010879:Piperazines; D017395:Plasminogen Activator Inhibitor 1; D062366:para-Aminobenzoates